Compare Amgen, Inc. (AMGN) vs iShares 0 3 Month Treasury Bond ETF (SGOV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs iShares 0 3 Month Treasury Bond ETF — how do they compare? Amgen, Inc. trades at $415.33 (market cap $224.14B), while iShares 0 3 Month Treasury Bond ETF trades at $100.52. The key difference: Amgen, Inc. pays a 2.43% dividend while iShares 0 3 Month Treasury Bond ETF pays none, and Amgen, Inc. is trading nearer its 52-week high, iShares 0 3 Month Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| AMGN | SGOV | |
|---|---|---|
Market Cap | $224.14B | — |
Sector | Health | Fixed Income |
52-Week High | $417.20 | $100.74 |
52-Week Low | $271.18 | $100.28 |
Enterprise Value | $267.45B | — |
Dividend Yield | 2.43% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amgen (AMGN) trades at $417.20, up 1.52% with strong technical momentum as price approaches resistance near $421. The company demonstrates robust fundamentals with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, marking the third consecutive quarterly beat. Revenue growth continues with 2025 revenue reaching $36.75 billion and 2026 projected at $38.1 billion, supported by strong performance from key products like Tezspire and Repatha.
Amgen presents a compelling growth story with raised 2026 guidance and strong product pipeline, though elevated valuation ratios (P/E 25.73, P/S 5.91) and high debt levels ($56.55 billion long-term debt) warrant caution. Analyst consensus remains bullish with 59% buy ratings and $394.69 price target, but current price trades above consensus target, suggesting near-term consolidation potential.
SGOV (iShares 0-3 Month Treasury Bond ETF) trades at $100.51 with minimal daily movement, reflecting its role as a stable cash alternative. The ETF maintains a bearish technical signal from moving averages while oscillators show neutral momentum. Recent institutional activity includes mixed positioning changes, with Bank of America increasing holdings while Deane Retirement Strategies significantly reduced exposure. The fund offers monthly distributions with a current yield around 3.8%, attracting defensive positioning amid market volatility.
SGOV provides principal protection and liquidity with minimal interest rate risk, making it suitable for conservative investors seeking yield above traditional savings. Key risks include Federal Reserve policy changes impacting short-term rates and inflation dynamics affecting real returns. The ETF's stability and monthly income stream offer defensive characteristics during economic uncertainty, though limited upside potential compared to equity investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About iShares 0 3 Month Treasury Bond ETF
SGOV provides exposure to ultra-short-term U.S. Treasury bills with maturities of three months or less. It functions as a high-liquidity cash alternative, seeking to provide current income while maintaining a stable net asset value and minimal interest rate risk.
Read more on SGOV →
